BCR and non-Hodgkin lymphoma: mTOR inhibition with everolimus and temsirolimus, PI3 K inhibition with parsaclisib are rescue treatments of relapsed and refractory NHL [90] By targeting the PI3 K/AKT/mTOR cascade, these treatments reduce BCR signaling.